Navigation Links
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
Date:3/4/2008

XYOTAX to be reviewed for PS2 first-line non-small cell lung cancer

indication

SEATTLE, March 4 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for XYOTAX(TM) (paclitaxel poliglumex, CT-2103) for first-line treatment of patients with non-small cell lung cancer (NSCLC) who have ECOG (Eastern Cooperative Oncology Group) performance status 2 (PS2). The application is based on a positive opinion CTI received from the EMEA's Scientific Advice Working Party, which agreed to review the application based on the existing results of the phase III clinical trials of XYOTAX, known as the STELLAR trials.

In the STELLAR 4 trial, single-agent XYOTAX resulted in comparable survival to gemcitabine or vinorelbine in first-line patients and, with the exception of neuropathy known to be associated with taxane therapy, demonstrated significant reduction in several clinically meaningful toxicities, such as severe neutropenia and infection, and in the requirement for transfusions and use of hematopoietic growth factor support. In addition to improved tolerability, XYOTAX offered more convenient administration compared to currently used treatments and a reduction in overall utilization of medical resources compared to gemcitabine or vinorelbine.

The application will be formally reviewed for validation by the end of March. Upon validation, the marketing approval review process begins, which generally takes 15 to 18 months.

"This is an important milestone for CTI and demonstrates our commitment to bring XYOTAX to this underserved group of patients. Currently there are no approved treatments for first-line use in PS2 patients with non-small cell lung cancer. Every day counts when treating patients who may have an average life expectancy of only six months, so quality of life an
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
10. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
11. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... MINNEAPOLIS , Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: ... develops, manufactures and markets innovative proprietary products to treat ... the 27th Annual ROTH Conference on Tuesday, March 10, ... Brett Reynolds , Chief Financial Officer, will present ... one on one at the conference at the Ritz ...
(Date:2/27/2015)... and JERUSALEM , Feb. 27, 2015 ... octreotide capsules, its lead product for the orphan condition ... Series E financing round. Participants in the financing included ... an undisclosed blue chip public investment fund, as well ... Health Ventures, Abingworth and ARCH Venture Partners. ...
(Date:2/26/2015)... Feb. 27, 2015  Finesse expands office in ... announced the expansion of its operations in ... mid-March and access for customers is expected shortly afterward. ... located adjacent to the current office, the new premises ... team and allow Finesse to bring on more service ...
Breaking Medicine Technology:Uroplasty to Participate in the 27th Annual ROTH Conference 2Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3New Finesse Office in United Kingdom 2
... May 11 The DNA Medicine Institute announced today that ... the Bill & Melinda Gates Foundation.  The grant will support an innovative ... titled "Optomagnetic Finger Scanner for Malaria." , ... Dr. Chan,s project is one of 78 grants announced by ...
... CHANGCHUN, China and LOS ... Inc. (OTC Bulletin Board: CYXN) (the "Company" or,"China Yongxin"), one ... today,announced that on March 31st, 2010 , the Company,s ... as one of the,qualified pharmaceuticals distributors for Jilin ...
Cached Medicine Technology:DNA Medicine Institute Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research 2DNA Medicine Institute Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research 3China Yongxin Pharmaceuticals is Selected as one of the Qualified Pharmaceutical Distributors for Jilin Province 2China Yongxin Pharmaceuticals is Selected as one of the Qualified Pharmaceutical Distributors for Jilin Province 3
(Date:2/28/2015)... 28, 2015 In recent years Medical Marijuana ... practicing physicians as a way for them to expand their ... Cannabis as medicine. Since the FDA still lists Cannabis as ... available to licensed physicians that can help guide them ... Deborah Malka in Santa Cruz, CA is a leader ...
(Date:2/28/2015)... Portland, OR (PRWEB) February 28, 2015 ... Duncan Fletcher of Game Change ... and Shannon Leinert about the benefits of athlete development ... underscores some of the unique challenges that athletes face ... on-field and future success. , Fletcher became involved in ...
(Date:2/28/2015)... 2015 With their commitment to achieving ... an additional exercise to their already robust library of ... most commonly known as, is often performed on a ... executed in a relatively safe manner and can be ... The full description of “Rope Pulls” is located in ...
(Date:2/28/2015)... 28, 2015 The Classic Denture ... a new special. Throughout all of March patients ... , This service can help overall mouth ... pain. Patients may notice certain symptoms that suggest the ... These symptoms include: , 1.    Pain, clicking, and popping in ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate tax ... business consulting services in addition to a variety of ... succession planning. Company finances are a complicated matter that ... of this, complex Canadian tax laws can make it ... result, Mew and Company works to advise their clients ...
Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2
... BELLEVUE, Wash., Sept. 11 The Citizens,Committee for the ... with,Oklahoma Sen. Tom Coburn that there is a serious ... Suicide Prevention Act -- that could,ultimately prevent military veterans ... defend., The problem, as pointed out by Sen. ...
... Thanks to a $1.6 million grant from the Welch ... launching a new initiative to develop innovative computational and ... drugs and molecular tools for biomedical science. , The ... Gulf Coast Consortium for Chemical Genomics (GCC CG) to ...
... with the breast cancer susceptibility gene BRCA1 often remove ... they believe fuels cancer growth. Yet they also know ... ovarian cancer that might develop. That paradox has led ... involved in cancer development and whether removal of ovaries ...
... Inc. (Pink Sheets: MSITF) wishes to announce that it has,completed ... Hepatitis C,test kit in Europe. Completion of this testing will ... EU approval would allow the Company to expand its ... It is anticipated that,when EU approval is received that it ...
... Sept. 11 Responding to a lawsuit by ... national medical,licensing examination, the National Board of Medical ... the needs of breastfeeding mothers as well as,other ... first priority for this test, accepted as evidence ...
... treatment, reseachers say , TUESDAY, Sept. 11 (HealthDay News) ... believe they may have found the disease,s genetic on/off ... to the development of better treatments, the team said. ... mouse model for schizophrenia by inserting the mutant Disrupted-In-Schizophrenia ...
Cached Medicine News:Health News:CCRKBA Backs Sen. Coburn's Opposition to Tenets of H.R. 327 2Health News:Welch Foundation gives $1.6 million for drug discovery research 2Health News:Welch Foundation gives $1.6 million for drug discovery research 3Health News:New clues to breast cancer development in high-risk women 2Health News:New clues to breast cancer development in high-risk women 3Health News:New clues to breast cancer development in high-risk women 4Health News:Medical Services International Inc. Completes Testing for European Union (EU) Application 2Health News:Public Health and Need for Consistent Standards Preclude Exception for Breastfeeding Mother in National Medical Licensing Test 2Health News:Schizophrenia Gene May Have On/Off Switch 2
... steps any hospital or health system can ... most effective tools available for physicians and ... documentation and electronic medical record (EMR) system, ... goal. In fact, its the most reliable ...
... instruments have been designed to provide ... tool for situations requiring precise hemostasis. ... 25 gauge intraocular, bipolar, diathermy instruments. ... target tissues for fine-tip hemostasis or ...
... clinician documentation and electronic medical record (EMR) ... specific needs of intensive care units and ... clinical functionality has secured its place as ... critical care, and its the most reliable ...
... itself to over 2,000 medical clinics nation ... user in mind, ChartingPlus relies heavily on ... features to improve documentation quality and increase ... Our medical content is specific to your ...
Medicine Products: